习近平青年观在高校思政教育中的应用研究

党的十八大以来,习近平总书记着眼于我国青年群体的发展,从实现中国梦的高度,提出了众多富有创见的新观点,深刻回答了新时代我国的高等教育要"培养什么样的人、如何培养人、为谁培养人""如何认识青年学生、如何教育引领青年学生、如何发挥青年学生作用"[1]等一系列重大问题,形成了内涵丰富的思想理论体系。习近平青年观,不仅是习近平新时代中国特色社会主义思想的重要组成部分,亦是新时代党做好青年工作的根本遵循。因此,深入挖掘习近平青年观的内涵,将其应用于高校思想政治教育的实践,无论对于高校思政工作的有效开展,还是对于大学生的成长成才都具有重要意义

Clinical analysis of perimenopausal women presenting initially with dry eye symptom

目的探讨围绝经期妇女的干眼症状与干眼病诊断的相关性。方法分析56例具有干眼症状的围绝经期妇女眼部检查的临床资料,观察主诉为干眼症状患者的干眼病确诊率及其关系。结果56例以干眼症状为主要表现的围绝经期妇女,确诊水液缺乏型干眼17例(30.4%),蒸发过强型干眼12例(21.4%),混合型干眼8例(14.3%);不能诊断干眼病的19例(33.9%),最终诊断为围绝经期综合征。结论围绝经期妇女干眼病确诊率较高(66.1%),但部分干眼症状可以只是围绝经期综合征的精神神经症状的一种表现,临床诊断干眼应慎重。 【英文摘要】 Objective Diagnosis and treatment of dry eye are important for improving living quality.Present paper was to investigate the correlation between dry eye manifestations and diagnosis of dry eye disease in perimenopausal women.MethodsThe clinical data of 56 perimenopausal women presenting initially with dry eye symptoms including ocular symptoms,slit-lamp examination,tear film break-up time,basal and reflex Schirmer test,vital staining(fluorescence and rose bangle),and meibomian gland dysfunction examination ..

Twelve degree freedom flight simulator performance test device

本发明提供一种十二自由度航天模拟器对接性能试验装置，包括二维平动驱动单元、主动偏航驱动单元、被动偏航驱动单元、主动航天模拟器和被动航天模拟器；主、被动偏航驱动单元分别设置于二维平动驱动单元两端，主动航天模拟器设置于主动偏航驱动单元上，被动航天模拟器设置于被动偏航驱动单元上；主动偏航驱动单元带动主动航天模拟器，模拟对接机构的主动端；被动偏航驱动单元和被动航天模拟器，模拟对接机构的被动端；本发明航天模拟器各自由度之间运动耦合性小，各自由度实现灵敏、可靠，运动范围大，运动轨迹不受限制，采用气浮技术模拟精度高

我国城市大气化石源CO_2的~(14)C示踪研究进展

化石燃料等排放是大气CO_2浓度增加的主要原因,而城市是碳排放研究的热点区域。获取化石源CO_2 (CO_(2ff))的时空变化特征,可以为政府的宏观决策及参与国际碳减排谈判提供重要的科学数据。近十年来我国科技人员在运用~(14)C示踪城市大气CO_(2ff)的研究方面取得了一些重要进展:通过大气、树轮和一年生植物样品~(14)C的分析,获得了不同时间尺度和空间尺度CO_(2ff)的变化特征,发现北方城市是减排的重点。CO_(2ff)与PM_(2.5)关系的研究表明,控制大气污染物可以同时降低CO_(2ff)排放,存在减排的协同效应。WRF-CHEM模式模拟分析了关中地区CO_(2ff)的传输,并结合Δ~(14)CO_2和 δ~(13)C对CO_(2ff)的来源进行解析,发现西安CO_(2ff)主要来源于本地燃煤的排放。~(14)C示踪获得的CO_(2ff)浓度与统计的碳排放量变化趋势和幅度基本一致,可以相互校验,保证数据的可靠性。为此建议尽快建立我国城市大气Δ~(14)CO_2观测网,投入更多的人力物力推进这项研究,服务于国家碳减排任务

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials